دورية أكاديمية
Minimal Antigenic Evolution after a Decade of Norovirus GII.4 Sydney_2012 Circulation in Humans.
العنوان: | Minimal Antigenic Evolution after a Decade of Norovirus GII.4 Sydney_2012 Circulation in Humans. |
---|---|
المؤلفون: | Parra GI; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Tohma K; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Ford-Siltz LA; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Eguino P; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Kendra JA; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Pilewski KA; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA., Gao Y; Division of Viral Products, Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, Maryland, USA. |
المصدر: | Journal of virology [J Virol] 2023 Feb 28; Vol. 97 (2), pp. e0171622. Date of Electronic Publication: 2023 Jan 23. |
نوع المنشور: | Journal Article; Research Support, U.S. Gov't, P.H.S. |
اللغة: | English |
بيانات الدورية: | Publisher: American Society For Microbiology Country of Publication: United States NLM ID: 0113724 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-5514 (Electronic) Linking ISSN: 0022538X NLM ISO Abbreviation: J Virol Subsets: MEDLINE |
أسماء مطبوعة: | Publication: Washington Dc : American Society For Microbiology Original Publication: Baltimore, American Society for Microbiology. |
مواضيع طبية MeSH: | Caliciviridae Infections*/virology , Norovirus*/classification , Norovirus*/genetics , Antigens, Viral*/genetics, Humans ; Antibodies, Monoclonal/metabolism ; Capsid Proteins/genetics ; Epitopes/genetics ; Gastroenteritis/virology ; Genotype ; Phylogeny ; Evolution, Molecular |
مستخلص: | Norovirus is a major human pathogen that can cause severe gastroenteritis in vulnerable populations. The extensive viral diversity presented by human noroviruses constitutes a major roadblock for the development of effective vaccines. In addition to the large number of genotypes, antigenically distinct variants of GII.4 noroviruses have chronologically emerged over the last 3 decades. The last variant to emerge, Sydney_2012, has been circulating at high incidence worldwide for over a decade. We analyzed 1449 capsid sequences from GII.4 Sydney_2012 viruses to determine genetic changes indicative of antigenic diversification. Phylogenetic analyses show that Sydney_2012 viruses scattered within the tree topology with no single cluster dominating during a given year or geographical location. Fourteen residues presented high variability, 7 of which mapped to 4 antigenic sites. Notably, ~52% of viruses presented mutations at 2 or more antigenic sites. Mutational patterns showed that residues 297 and 372, which map to antigenic site A, changed over time. Virus-like particles (VLPs) developed from wild-type Sydney_2012 viruses and engineered to display all mutations detected at antigenic sites were tested against polyclonal sera and monoclonal antibodies raised against Sydney_2012 and Farmington_Hills_2002 VLPs. Minimal changes in reactivity were detected with polyclonal sera and only 4 MAbs lost binding, with all mapping to antigenic site A. Notably, reversion of residues from Sydney_2012 reconstituted epitopes from ancestral GII.4 variants. Overall, this study demonstrates that, despite circulating for over a decade, Sydney_2012 viruses present minimal antigenic diversification and provides novel insights on the diversification of GII.4 noroviruses that could inform vaccine design. IMPORTANCE GII.4 noroviruses are the major cause of acute gastroenteritis in all age groups. This predominance has been attributed to the continued emergence of phylogenetically discrete variants that escape immune responses to previous infections. The last GII.4 variant to emerge, Sydney_2012, has been circulating at high incidence for over a decade, raising the question of whether this variant is undergoing antigenic diversification without presenting a major distinction at the phylogenetic level. Sequence analyses that include >1400 capsid sequences from GII.4 Sydney_2012 showed changes in 4 out of the 6 major antigenic sites. Notably, while changes were detected in one of the most immunodominant sites over time, these resulted in minimal changes in the antigenic profile of these viruses. This study provides new insights on the mechanism governing the antigenic diversification of GII.4 norovirus that could help in the development of cross-protective vaccines to human noroviruses. |
References: | J Virol. 2007 Sep;81(18):9932-41. (PMID: 17609280) Nat Rev Microbiol. 2021 Jul;19(7):409-424. (PMID: 34075212) J Virol. 2014 Jan;88(2):829-37. (PMID: 24173225) J Virol. 2015 Aug;89(15):7776-85. (PMID: 25995258) J Infect Dis. 2022 Apr 1;225(7):1205-1214. (PMID: 32179892) J Infect Dis. 2009 Sep 1;200(5):802-12. (PMID: 19627248) Emerg Infect Dis. 2014 Jun;20(6):1016-8. (PMID: 24857806) PLoS Pathog. 2012;8(10):e1002921. (PMID: 23093932) Cell Rep Med. 2021 Mar 30;2(4):100225. (PMID: 33948566) Gut Microbes. 2021 Jan-Dec;13(1):1-13. (PMID: 33783322) J Infect Dis. 2012 Nov;206(9):1386-93. (PMID: 22927452) Virus Evol. 2019 Nov 25;5(2):vez048. (PMID: 32161666) Virus Evol. 2018 Jun 08;4(1):vey016. (PMID: 29942656) J Clin Microbiol. 2017 Jul;55(7):2208-2221. (PMID: 28490488) Gastroenterology. 2002 Jun;122(7):1967-77. (PMID: 12055602) J Virol. 2012 Jul;86(13):7414-26. (PMID: 22532688) Cell Rep Med. 2021 Apr 20;2(4):100257. (PMID: 33948584) Nat Rev Genet. 2022 Sep;23(9):547-562. (PMID: 35459859) Nat Med. 2003 May;9(5):548-53. (PMID: 12692541) J Infect Dis. 2020 Feb 18;221(5):739-743. (PMID: 31613328) J Clin Microbiol. 2004 Sep;42(9):3950-7. (PMID: 15364974) Science. 1999 Oct 8;286(5438):287-90. (PMID: 10514371) Nature. 2017 Apr 20;544(7650):309-315. (PMID: 28405027) Science. 2004 Jan 16;303(5656):327-32. (PMID: 14726583) Rev Med Virol. 2022 Sep;32(5):e2354. (PMID: 35481689) Cell. 2021 Mar 4;184(5):1171-1187.e20. (PMID: 33621484) Proc Natl Acad Sci U S A. 2021 Mar 16;118(11):. (PMID: 33836574) Clin Vaccine Immunol. 2015 Aug;22(8):923-9. (PMID: 26041041) Gastroenterology. 2018 Dec;155(6):1898-1907. (PMID: 30170116) Nature. 2021 Dec;600(7889):408-418. (PMID: 34880490) PLoS One. 2013 Jun 21;8(6):e67592. (PMID: 23805319) Virus Evol. 2016 Apr 09;2(1):vew007. (PMID: 27774300) PLoS Pathog. 2021 Jul 13;17(7):e1009744. (PMID: 34255807) J Infect Dis. 2010 Oct 15;202(8):1212-8. (PMID: 20815703) mBio. 2022 Oct 26;13(5):e0186122. (PMID: 36102514) Viruses. 2019 Jun 08;11(6):. (PMID: 31181749) Cell Rep. 2022 Apr 12;39(2):110689. (PMID: 35417705) Proc Natl Acad Sci U S A. 2016 Mar 22;113(12):E1701-9. (PMID: 26951657) mBio. 2019 Sep 24;10(5):. (PMID: 31551337) Syst Biol. 2010 May;59(3):307-21. (PMID: 20525638) PLoS Pathog. 2017 Jan 19;13(1):e1006136. (PMID: 28103318) |
معلومات مُعتمدة: | Z01 BK 04012 LHV HHS | U.S. Food and Drug Administration (FDA) |
فهرسة مساهمة: | Keywords: antigenic variation; calicivirus; gastroenteritis; norovirus; phylogenetic analysis |
المشرفين على المادة: | 0 (Antibodies, Monoclonal) 0 (Capsid Proteins) 0 (Epitopes) 0 (Antigens, Viral) |
تواريخ الأحداث: | Date Created: 20230123 Date Completed: 20230307 Latest Revision: 20230315 |
رمز التحديث: | 20231215 |
مُعرف محوري في PubMed: | PMC9973034 |
DOI: | 10.1128/jvi.01716-22 |
PMID: | 36688654 |
قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!